TY - JOUR
T1 - Tricuspid Regurgitation Impact on Outcomes (TRIO)
T2 - A Simple Clinical Risk Score
AU - Lara-Breitinger, Kyla M.
AU - Scott, Christopher G.
AU - Nkomo, Vuyisile T.
AU - Pellikka, Patricia A.
AU - Kane, Garvan C.
AU - Chaliki, Hari P.
AU - Shapiro, Brian P.
AU - Eleid, Mackram F.
AU - Alkhouli, Mohamad
AU - Greason, Kevin L.
AU - Pislaru, Sorin V.
AU - Rihal, Charanjit S.
N1 - Publisher Copyright:
© 2022 Mayo Foundation for Medical Education and Research
PY - 2022/8
Y1 - 2022/8
N2 - Objective: To determine which clinical variables infer the highest risk for mortality in patients with notable tricuspid regurgitation (TR) and to develop a clinical assessment tool (the Tricuspid Regurgitation Impact on Outcomes [TRIO] score). Patients and Methods: A single-center retrospective cohort of 13,608 patients with undifferentiated moderate to severe TR at the time of index echocardiography between January 1, 2005, and December 31, 2016, was included. Baseline demographic and clinical data were obtained. Patients were randomly assigned to a training (N=10,205) and a validation (N=3403) cohort. Median follow-up was 6.5 years (interquartile range, 0.8 to 11.0 years). Variables associated with mortality were identified by Cox proportional hazards methods. A geographically distinct cohort of 7138 patients was used for further validation. The primary end point was all-cause mortality over 10 years. Results: The 5-year probability of death was 53% for moderate TR, 63% for moderate-severe TR (hazard ratio [HR], 1.24 [95% CI, 1.17 to 1.31]; P<.001 vs moderate), and 71% for severe TR (HR, 1.55 [95% CI, 1.47 to 1.64]; P<.001 vs moderate). Factors associated with all-cause mortality on multivariate analysis included age 70 years or older, male sex, creatinine level greater than 2 mg/dL, congestive heart failure, chronic lung disease, aspartate aminotransferase level of 40 U/L or greater, heart rate of 90 beats/min or greater, and severe TR. Variables were assigned 1 or 2 points (HR, >1.5) and added to compute the TRIO score. The score was associated with all-cause mortality (C statistic = 0.67) and was able to separate patients into risk categories. Findings were similar in the second, independent and geographically distinct cohort. Conclusion: The TRIO score is a simple clinical tool for risk assessment in patients with notable TR. Future prospective studies to validate its use are warranted.
AB - Objective: To determine which clinical variables infer the highest risk for mortality in patients with notable tricuspid regurgitation (TR) and to develop a clinical assessment tool (the Tricuspid Regurgitation Impact on Outcomes [TRIO] score). Patients and Methods: A single-center retrospective cohort of 13,608 patients with undifferentiated moderate to severe TR at the time of index echocardiography between January 1, 2005, and December 31, 2016, was included. Baseline demographic and clinical data were obtained. Patients were randomly assigned to a training (N=10,205) and a validation (N=3403) cohort. Median follow-up was 6.5 years (interquartile range, 0.8 to 11.0 years). Variables associated with mortality were identified by Cox proportional hazards methods. A geographically distinct cohort of 7138 patients was used for further validation. The primary end point was all-cause mortality over 10 years. Results: The 5-year probability of death was 53% for moderate TR, 63% for moderate-severe TR (hazard ratio [HR], 1.24 [95% CI, 1.17 to 1.31]; P<.001 vs moderate), and 71% for severe TR (HR, 1.55 [95% CI, 1.47 to 1.64]; P<.001 vs moderate). Factors associated with all-cause mortality on multivariate analysis included age 70 years or older, male sex, creatinine level greater than 2 mg/dL, congestive heart failure, chronic lung disease, aspartate aminotransferase level of 40 U/L or greater, heart rate of 90 beats/min or greater, and severe TR. Variables were assigned 1 or 2 points (HR, >1.5) and added to compute the TRIO score. The score was associated with all-cause mortality (C statistic = 0.67) and was able to separate patients into risk categories. Findings were similar in the second, independent and geographically distinct cohort. Conclusion: The TRIO score is a simple clinical tool for risk assessment in patients with notable TR. Future prospective studies to validate its use are warranted.
UR - http://www.scopus.com/inward/record.url?scp=85135321396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135321396&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2022.05.015
DO - 10.1016/j.mayocp.2022.05.015
M3 - Article
C2 - 35933133
AN - SCOPUS:85135321396
SN - 0025-6196
VL - 97
SP - 1449
EP - 1461
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 8
ER -